In the case of Prostate-Specific Membrane Antigen (PSMA)-targeting agents, Baranski et al. reported increased cellular internalization and tumor uptake following the incorporation of IRDye800CW or DyLight800. This evidence concerns the gene FOLH1 and neoplasm.